MT Newswires
Update: Market Chatter: Eli Lilly Could Get FDA Decision for Weight-Loss Pill Orforglipron by March 2026
➖
AI Sentiment
Neutral
5/10
- Home
- NVO
NVO
Novo Nordisk A/S
as of 12-15-2025 3:35pm EST
$50.31
+$0.21
+0.41%
With roughly one-third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (contributing less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Chart Type:
Time Range:
| Founded: | 1923 | Country: | Denmark |
| Employees: | N/A | City: | N/A |
| Market Cap: | 212.7B | IPO Year: | N/A |
| Target Price: | $54.25 | AVG Volume (30 days): | 18.5M |
| Analyst Decision: | Buy | Number of Analysts: | 11 |
| Dividend Yield: | Dividend Payout Frequency: | Semi-Annual | |
| EPS: | 3.67 | EPS Growth: | 10.06 |
| 52 Week Low/High: | $43.08 - $111.17 | Next Earning Date: | 02-04-2026 |
| Revenue: | $49,580,393,058 | Revenue Growth: | 16.64% |
| Revenue Growth (this year): | 7.77% | Revenue Growth (next year): | 1.86% |
AI-Powered NVO Daily Prediction
Machine learning model trained on 25+ technical indicators
Updated a day ago
AI Recommendation
hold
Model Accuracy: 77.42%
77.42%
Confidence
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Latest Novo Nordisk A/S News
NVO Breaking Stock News: Dive into NVO Ticker-Specific Updates for Smart Investing
Investor's Business Daily
Eli Lilly Rises, Again, After EMA Groups Recommends Mounjaro For Children As Young As 10
📈
AI Sentiment
Highly Positive
8/10
MT Newswires
Sector Update: Health Care Stocks Edge Higher Friday Afternoon
📊
AI Sentiment
Positive
6/10
GuruFocus.com
Novo's Next Shot at Dominance: High-Dose Wegovy Takes Aim at Lilly's Zepbound
📈
AI Sentiment
Highly Positive
8/10
Barrons.com
Novo Nordisk Is Selling Ozempic for $24 a Week in India. Why It’s So Cheap.
📉
AI Sentiment
Negative
3/10
MT Newswires
European Equities Traded in the US as American Depositary Receipts Lower in Friday Trading; Shares Still Up This Week
➖
AI Sentiment
Neutral
4/10
Compare NVO vs Leading Stocks
See how NVO stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "NVO Novo Nordisk A/S - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.